Heart Failure

>

Latest News

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study
ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

April 1st 2025

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Women's  Heart Health News: 5 Studies from ACC.25 / image credit  ©Hamza/stock.adobe.com
Women's Heart Health: 5 Studies from ACC.25

March 28th 2025

Marijuana Use Tied to Increased Risk for Myocardial Infarction in People Aged 50 Years and Younger / Image credit: ©Konstiantyn Zapylaie - ©Konstiantyn Zapylaie - stock.adobe.com
Marijuana Use Tied to Increased Risk for Myocardial Infarction in People Aged 50 Years and Younger

March 24th 2025

Finerenone Improves Outcomes in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction / Image credit: ©tashatuvango/AdobeStock
Finerenone Improves Outcomes in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction

September 4th 2024

Finerenone Phase 3 Data Show Benefit in HFpEF, Promise for New Indication
Finerenone Phase 3 Data Show Benefit in HFpEF, Promise for New Indication

August 6th 2024

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.